Biocad CJSC Reports Retrospective Cohort Analysis of BCD-020 (biosimilar, rituximab) for Pediatric Patients with Lupus Nephritis
Shots:
- The retrospective cohort analysis published in Biomedicines evaluating BCD-020 in 25 pediatric patients (n=10 boys & 15 girls) who failed conventional non-biologic treatment
- The results showed that BCD-020 was safe & effective in pediatric patients & minimized the side effects of standard therapy with 80% reductions in SLEDAI, the anti-double-stranded DNA level, proteinuria, hematuria, C4 complement, erythrocyte sedimentation rate, and the median corticosteroid dose, proportion of patients without corticosteroids was reduced after rituximab administration
- Renal function was improved, the GFR increased & hemodialysis was interrupted in patients who previously required it. BCD-020, the first Russian rituximab biosimilar approved for lymphoma in Russia & some CIS countries
Ref: Biocad | Image: Biocad
Related News:- Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
